• Fri, March 3, 2023
Mark Breidenbach Maintained (SYRS) at Buy with Decreased Target to $13 on, Mar 3rd, 2023
Mark Breidenbach of Oppenheimer, Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Buy with Decreased Target from $15 to $13 on, Mar 3rd, 2023.
Mark has made no other calls on SYRS in the last 4 months.
There are 2 other peers that have a rating on SYRS. Out of the 2 peers that are also analyzing SYRS, 0 agree with Mark's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Mark
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $20 on, Thursday, January 5th, 2023
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $16 on, Tuesday, November 15th, 2022
Like: 👍
